Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization
S Li, J Fu, H Ma, MY Mapara, S Lentzsch - Leukemia, 2013 - nature.com
S Li, J Fu, H Ma, MY Mapara, S Lentzsch
Leukemia, 2013•nature.com2 Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment
cytogenetic abnormalities are predictive of induction success, cumulative incidence of
relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results
from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336. 3 Garcia-
Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda WG et al. Phase I study
of the combination of 5-azacitidine sequentially with high-dose lenalidomide in higher-risk …
cytogenetic abnormalities are predictive of induction success, cumulative incidence of
relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results
from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336. 3 Garcia-
Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda WG et al. Phase I study
of the combination of 5-azacitidine sequentially with high-dose lenalidomide in higher-risk …
2 Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.
3 Garcia-Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda WG et al. Phase I study of the combination of 5-azacitidine sequentially with high-dose lenalidomide in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Blood 2011; 118: abstract 2613. 4 Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012; 120: 4945–4951. 5 Heise C, Carter T, Schafer P, Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del (5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 2010; 10: 1663–1672.
nature.com
